Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 31.
doi: 10.1111/apt.70306. Online ahead of print.

Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes

Na Tian  1 , Tie Xiao  1 , Tianyi Xia  2 , Hai-Yang Yuan  1 , Michael D Shapiro  3 , Gregory Y H Lip  4   5 , Cheng-Han Fanren  6 , Li-You Lian  1 , Chen-Xiao Huang  1 , Yi-Xuan Wei  1 , Giovanni Targher  7   8 , Christopher D Byrne  9 , Cheng-Lv Hong  6 , Shenghong Ju  2 , Ming-Hua Zheng  1   10   11 ; WMU MAFLD Clinical Research Working Group
Collaborators, Affiliations

Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes

Na Tian et al. Aliment Pharmacol Ther. .

Abstract

Background and aims: Liver fibrosis may be associated with coronary artery disease (CAD) and adverse cardiovascular outcomes, but data remain limited. This study aimed to explore the relationship between liver fibrosis and the incidence of CAD, stent thrombosis (ST), in-stent restenosis (ISR) and long-term clinical outcomes.

Methods: Two cohorts were analysed: the UK Biobank (UKB) cohort examined liver fibrosis and CAD incidence and clinical outcomes in the general population, while the Wenzhou cohort assessed its relationship with ST and ISR and long-term outcomes in post-PCI patients. CAD incidence was defined as coronary stenosis ≥ 50% or clinical events, such as myocardial ischaemia, myocardial infarction and acute coronary syndrome. ST was confirmed via angiography, and ISR was defined as ≥ 50% stenosis within the stent. Major adverse cardiovascular events (MACE) included all-cause mortality, myocardial infarction, heart failure and stroke. Liver fibrosis was assessed using FIB-4, categorised as ≤ 1.3, 1.3-2.67 and > 2.67.

Results: 394,625 participants were included. In the UKB cohort (n = 380,638), 7102 (1.9%) had FIB-4 > 2.67. Over 14.4 years, FIB-4 > 2.67 was associated with higher CAD incidence (aHR = 1.41, p < 0.001) and MACE (aHR = 1.69, p < 0.001). In the Wenzhou cohort (n = 13,987), 3173 (22.7%) had FIB-4 > 2.67. Over 3.0 years, FIB-4 > 2.67 was associated with increased risks of ST and ISR (aHR = 1.34, p = 0.001) and MACE (aHR = 1.97, p < 0.001).

Conclusions: Liver fibrosis is common among patients with CAD and is associated with CAD incidence, stent thrombosis, restenosis and long-term cardiovascular risk.

Keywords: coronary artery disease; fibrosis‐4 score; major adverse cardiovascular events; percutaneous coronary intervention; restenosis; stent thrombosis.

PubMed Disclaimer

References

    1. C. W. Tsao, A. W. Aday, Z. I. Almarzooq, et al., “Heart Disease and Stroke Statistics‐2022 Update: A Report From the American Heart Association,” Circulation 145, no. 8 (2022): e153–e639, https://doi.org/10.1161/CIR.0000000000001052.
    1. X. D. Zhou, Q. F. Chen, G. Targher, et al., “Global Burden of Disease Attributable to Metabolic Risk Factors in Adolescents and Young Adults Aged 15–39, 1990–2021,” Clinical Nutrition 43, no. 12 (2024): 391–404, https://doi.org/10.1016/j.clnu.2024.11.016.
    1. J. Ye, X. Zhuang, X. Li, et al., “Novel Metabolic Classification for Extrahepatic Complication of Metabolic Associated Fatty Liver Disease: A Data‐Driven Cluster Analysis With International Validation,” Metabolism 136 (2022): 155294, https://doi.org/10.1016/j.metabol.2022.155294.
    1. X. D. Zhou, Q. F. Chen, W. Yang, et al., “Burden of Disease Attributable to High Body Mass Index: An Analysis of Data From the Global Burden of Disease Study 2021,” EClinicalMedicine 76 (2024): 102848, https://doi.org/10.1016/j.eclinm.2024.102848.
    1. F. L. J. Visseren, F. Mach, Y. M. Smulders, et al., “2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice,” European Heart Journal 42, no. 34 (2021): 3227–3337, https://doi.org/10.1093/eurheartj/ehab484.

LinkOut - more resources